What is HC Wainwright’s Forecast for PolyPid Q3 Earnings?

PolyPid Ltd. (NASDAQ:PYPD) – Analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of PolyPid in a research report issued on Wednesday, August 12th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.41) per share for the quarter, down from their previous estimate of ($0.40). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($1.67) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.44) EPS.

A number of other equities research analysts have also issued reports on the stock. Craig Hallum set a $12.00 price objective on shares of PolyPid in a report on Wednesday, July 22nd. Weiss Ratings upgraded PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.33.

PolyPid Price Performance

PolyPid stock opened at $4.78 on Friday. PolyPid has a 1 year low of $3.06 and a 1 year high of $5.73. The stock has a market cap of $91.20 million, a price-to-earnings ratio of -3.23 and a beta of 1.41. The firm has a 50-day moving average of $4.73 and a two-hundred day moving average of $4.57.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03.

Institutional Trading of PolyPid

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AIGH Capital Management LLC acquired a new position in PolyPid in the 2nd quarter worth $7,644,000. ADAR1 Capital Management LLC bought a new stake in shares of PolyPid in the 4th quarter valued at about $451,000. Renaissance Technologies LLC acquired a new stake in PolyPid during the 1st quarter worth about $81,000. Jane Street Group LLC bought a new position in shares of PolyPid in the 4th quarter worth $66,000. Finally, XTX Topco Ltd lifted its stake in PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after acquiring an additional 10,888 shares in the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.